Comera Life Sciences Announces Collaboration with Quality Chemical Laboratories to Secure Proprietary Supply of SQore Excipients
July 20, 2023 08:00 ET
|
Comera Life Sciences
– Ownership of proprietary sourcing for U.S.-manufactured lead SQore excipients allows for full control over supply chain and greater flexibility to support product development needs – WOBURN,...
Comera Life Sciences Reports Financial Results for First Quarter 2023 and Recent Business Highlights
May 11, 2023 08:30 ET
|
Comera Life Sciences
– Significant progress in Comera’s ongoing research collaboration with Regeneron, a leading U.S. biotechnology company – – Further development of Comera’s pipeline candidate CLS-001 (SQ...
Comera Life Sciences to Participate in Four Upcoming Conferences
April 27, 2023 08:00 ET
|
Comera Life Sciences
WOBURN, Mass., April 27, 2023 (GLOBE NEWSWIRE) -- Comera Life Sciences Holdings, Inc. (Nasdaq: CMRA) (“Company” or “Comera”), a life sciences company developing a new generation of bio-innovative...
Comera Life Sciences Announces Expansion of Patent Portfolio Underlying Core Excipient Technology
April 03, 2023 08:30 ET
|
Comera Life Sciences
– Notice of Allowance of U.S. patent application received for expansion of core viscosity reduction claims for excipients in SQore™ platform – – Patent granted in South Korea and Notice of...
Comera Life Sciences Reports Financial Results for Fourth Quarter and Full Year 2022 and Recent Business Highlights
March 16, 2023 08:00 ET
|
Comera Life Sciences
– Extended and broadened its ongoing research collaboration with Regeneron, a leading U.S. biotechnology company – – Announced CLS-001 as subcutaneous formulation of vedolizumab, a currently marketed...
Comera Life Sciences to Present at 22nd Annual PepTalk Conference
January 12, 2023 16:15 ET
|
Comera Life Sciences
WOBURN, Mass., Jan. 12, 2023 (GLOBE NEWSWIRE) -- Comera Life Sciences Holdings, Inc. (Nasdaq: CMRA) (“Company” or “Comera”), a life sciences company developing a new generation of bio-innovative...
Comera Life Sciences to Present at Upcoming Biotech Showcase Investor Conference
January 05, 2023 08:00 ET
|
Comera Life Sciences
WOBURN, Mass., Jan. 05, 2023 (GLOBE NEWSWIRE) -- Comera Life Sciences Holdings, Inc. (Nasdaq: CMRA), a life sciences company developing a new generation of bio-innovative biologic medicines to...
Comera Life Sciences Closes $3.6 Million Private Placement Priced At-the-Market under Nasdaq Rules
January 04, 2023 16:15 ET
|
Comera Life Sciences
WOBURN, Mass., Jan. 04, 2023 (GLOBE NEWSWIRE) -- Comera Life Sciences Holdings, Inc. (Nasdaq: CMRA), a life sciences company developing a new generation of bio-innovative biologic medicines to...
Comera Life Sciences to Participate in the Benchmark Company’s Upcoming Discovery One-on-One Investor Conference
November 17, 2022 16:05 ET
|
Comera Life Sciences
WOBURN, Mass., Nov. 17, 2022 (GLOBE NEWSWIRE) -- Comera Life Sciences Holdings, Inc. (Nasdaq: CMRA), a life sciences company developing a new generation of bio-innovative biologic medicines to...
Comera Life Sciences Reports Financial Results for Third Quarter 2022 and Business Highlights
November 10, 2022 08:00 ET
|
Comera Life Sciences
– Extended and broadened its ongoing research collaboration with Regeneron, a leading U.S. biotechnology company – – Announces CLS-001 as subcutaneous formulation of vedolizumab, a currently marketed...